Maxim Group Maintains Buy Rating on CERo Therapeutics (CERO)

In a report released on May 30, analyst Jason McCarthy from Maxim Group maintained a Buy rating on CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) with a $3.00 price target. The optimistic rating update came after the company announced on the same day that it had dosed the first patient in its Phase 1 clinical trial of CER-1236, a novel cell therapy for acute myeloid leukemia (AML).

The dosing took place at the lead trial site and marked a significant milestone for the company. CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) is continuing monitoring post-infusion for key tolerability, safety, and efficacy endpoints.

A doctor examining a MRI scan and pointing to an image of a cancerous tumor.

It plans to feature the study and trial protocols at the 2025 Annual Meeting of the American Society of Clinical Oncology in Chicago, held from May 30 to June 3, highlighting CER-1236’s innovative approach, which combines the phagocytic receptor TIM-4 and T-cell co-stimulatory domains.

Since it involves both traditional cytotoxic T-cell mechanisms and phagocytosis, the analyst considers CER-1236’s novel mechanism to be a key derisking factor because of the structural similarity it holds to approved CAR-T therapies.

He further stated that the trial’s early-stage results are eagerly anticipated, as they could potentially reflect efficacy with only a few patients, similar to the initial successes of CD19 CAR therapies in late-stage hematological cancers. The study could make a considerable impact in a high-need oncology area, supporting the buy rating.

CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) is immunotherapy company that develops engineered T cell therapeutics for cancer treatment. Its platform eliminates tumor by redirecting patient-derived T cells, creating Chimeric Engulfment Receptor T (CER-T) cells for spanning solid tumors and hematological malignancies.

While we acknowledge the potential of CERO as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than CERO and that has 100x upside potential, check out our report about the cheapest AI stock.

READ NEXT: 10 Best Debt Free IT Penny Stocks To Buy and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.